Study explains why current BET inhibitors fail in cancer treatment
View as a Web Page
News Medical
 
  Hematology Hematology logo  
  The latest hematology news from News Medical  
 Study finds long COVID leaves a distinct immune signature in the bloodStudy finds long COVID leaves a distinct immune signature in the blood
 
Researchers identified a small panel of inflammatory and neurology-related blood proteins that may help distinguish long COVID from recovery or no prior infection, while also showing that booster vaccination did not appear to worsen these protein responses in this cohort.
 
 
 Study explains why current BET inhibitors fail in cancer treatmentStudy explains why current BET inhibitors fail in cancer treatment
 
For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations.
 
   Clinical trial tests laser therapy for vaginal dryness in breast cancer survivorsClinical trial tests laser therapy for vaginal dryness in breast cancer survivors
 
The Alliance for Clinical Trials in Oncology is now enrolling patients into a clinical trial aimed at helping women recover from the vaginal side effects of breast cancer treatment.
 
   Pennsylvania town faces fallout from Trump's environmental rule rollbackPennsylvania town faces fallout from Trump's environmental rule rollback
 
North America's largest coke plant hugs the west bank of Pennsylvania's Monongahela River, belching out emissions from turning superheated coal into a carbon-rich fuel.
 
   Precision medicine tools offer hope for patients with rare blood cancersPrecision medicine tools offer hope for patients with rare blood cancers
 
Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.
 
 OICR funds four Ontario teams to develop next-generation cancer therapies
 
OICR funds four Ontario teams to develop next-generation cancer therapiesBetter cancer care depends on better treatment options. That's why the Ontario Institute for Cancer Research (OICR) is supporting four Ontario-based research teams working to develop the next generation of cancer therapies that are designed to be more effective at destroying tumors, have reduced side effects, and make cancer less likely to return.
 
 
 Targeting super-enhancer mechanisms offers new strategies for cancer therapy
 
Targeting super-enhancer mechanisms offers new strategies for cancer therapySuper-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain malignancy, and create "transcriptional addiction" in cancer.
 
 
 Study identifies intersectional biases affecting care for sickle cell patients
 
Study identifies intersectional biases affecting care for sickle cell patientsIn season 1, episode 2 of the popular show The Pitt, a Black woman with sickle cell disease arrives at the emergency department in acute pain, only to be initially dismissed as drug-seeking.
 
 
 Study maps DNA methylation changes driving MDS stem cell dysfunction
 
Study maps DNA methylation changes driving MDS stem cell dysfunctionPublished on April 01, 2026, in Volume 2, article number 19 of the journal Immunity & Inflammation, a collaborative team led by Prof. Cao at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, along with Dr.
 
 
 Dynamic binding of linker histone H1 shapes flexible chromatin organization
 
DNA inside the nucleus is not packed as a rigid regular fiber-linker histone H1 dynamically binds and loosely "glues" nucleosomes together, creating a dynamic, fluid organization that can still support essential genome functions.
 
 
 Microneedle nanoparticle platform improves lymphatic imaging with high resolution
 
The lymphatic system plays a critical role in pathological conditions such as lymphedema and chronic inflammation to tumor metastasis, venous insufficiency, and impaired wound healing, making accurate evaluation of its structure and function increasingly important.
 
 
 New target CD43 may improve leukemia immunotherapy outcomes
 
Macrophages, much like Alice of "Alice in Wonderland," recognize and consume tumor cells that display "eat me" surface markers.
 
 
 Minimally-invasive stenting effectively treats painful post-thrombotic syndrome
 
A major multi-site clinical trial co-led by researchers at Washington University School of Medicine in St. Louis has shown that post-thrombotic syndrome - a common and often painful complication suffered by many people who have experienced blockages of major veins due to blood clots - can be effectively treated with a minimally invasive procedure.
 
 
 Experimental drug shows survival benefit in pancreatic cancer trial
 
Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis.
 
 
 Mezagitamab shows promise in treating immune thrombocytopenia patients
 
Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that the investigational medication mezagitamab can effectively boost platelet counts in patients with immune thrombocytopenia (ITP), an autoimmune disease characterized by elevated platelet destruction and reduced platelet production that increases bleeding risk and compromises quality of life.
 
 
 CAR T therapy induces remission in multiple autoimmune diseases
 
For the first time, scientists have used a cutting-edge cell therapy called CAR-T to treat a patient with three different life-threatening autoimmune diseases that had resisted years of treatment.
 
 
 Study reveals immune aging differs significantly between men and women
 
Statistics show clear differences in the population's immune system according to sex: men are more susceptible to infections and cancers, while women have stronger immune responses, which translate, for example, into better responses to vaccines.
 
Facebook X Instagram LinkedIn Vimeo
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd., NEO, 9 Charlotte St, Manchester, M1 4ET, UK

Manchester | Sydney | Boston

Copyright © 2000-2026